Corpus overview


MeSH Disease

Human Phenotype

Edema (2)

Dyspnea (1)

Asthma (1)

Melanoma (1)

Preeclampsia (1)


There are no transmission terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    Asthma HP and COVID-19 - A systematic review

    Authors: Natália F. Mendes; Carlos P. Jara; Eli Mansour; Eliana P. Araújo; Licio Velloso

    doi:10.21203/ Date: 2020-08-05 Source: ResearchSquare

    BackgroundSevere coronavirus disease-19 (COVID-19) presents with progressive dyspnea HP dyspnea MESHD, which results from acute lung inflammatory edema MESHD edema HP leading to hypoxia MESHD. As with other infectious diseases MESHD that affect the respiratory tract, asthma HP has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.MethodsHere, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to May 18, 2020, looking into the description of asthma HP asthma MESHD as a premorbid condition, which could indicate its potential involvement in disease progression.ResultsWe found 169 articles describing the clinical characteristics of 36,072 patients diagnosed with COVID-19. Asthma HP was reported as a premorbid condition in only 655 patients accounting for 1.8% of all patients.ConclusionsAs the global prevalence SERO of asthma HP is 4.4%, we conclude that either asthma HP asthma MESHD is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.

    Placental pathology in COVID-19

    Authors: Elisheva D Shanes; Leena B Mithal; Sebastian Otero; Hooman A Azad; Emily S Miller; Jeffery A Goldstein

    doi:10.1101/2020.05.08.20093229 Date: 2020-05-12 Source: medRxiv

    Objectives: To describe histopathologic findings in the placentas of women with COVID-19 during pregnancy. Methods: Pregnant women with COVID-19 delivering between March 18, 2020 and May 5, 2020 were identified. Placentas were examined and compared to historical controls and women with placental evaluation for a history of melanoma HP melanoma MESHD. Results: 16 placentas from patients with SARS-CoV-2 were examined (15 with live birth in the 3rd trimester 1 delivered in the 2nd trimester after intrauterine fetal demise). Compared to controls, third trimester placentas were significantly more likely to show at least one feature of maternal vascular malperfusion (MVM), including abnormal or injured maternal vessels, as well as delayed villous maturation, chorangiosis, and intervillous thrombi MESHD. Rates of acute and chronic inflammation MESHD were not increased. The placenta from the patient with intrauterine fetal demise showed villous edema MESHD edema HP and a retroplacental hematoma MESHD. Conclusions: Relative to controls, COVID-19 placentas show increased prevalence SERO of features of maternal vascular malperfusion (MVM), a pattern of placental injury reflecting abnormalities in oxygenation within the intervillous space associated with adverse perinatal outcomes. Only 1 COVID-19 patient was hypertensive MESHD despite the association of MVM with hypertensive disorders MESHD and preeclampsia HP. These changes may reflect a systemic inflammatory or hypercoagulable state influencing placental physiology.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.